DOP2015000215A - Sal de abexinostato novedosa, forma cristalina relacionada, método de preparación de esta y las composiciones farmacéuticas que la contienen - Google Patents

Sal de abexinostato novedosa, forma cristalina relacionada, método de preparación de esta y las composiciones farmacéuticas que la contienen

Info

Publication number
DOP2015000215A
DOP2015000215A DO2015000215A DO2015000215A DOP2015000215A DO P2015000215 A DOP2015000215 A DO P2015000215A DO 2015000215 A DO2015000215 A DO 2015000215A DO 2015000215 A DO2015000215 A DO 2015000215A DO P2015000215 A DOP2015000215 A DO P2015000215A
Authority
DO
Dominican Republic
Prior art keywords
crystalline form
novedosa
abexinostato
salt
preparation
Prior art date
Application number
DO2015000215A
Other languages
English (en)
Inventor
Anne Pimont-Garro
Philippe Letellier
Original Assignee
Pharmacyclics Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48521256&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DOP2015000215(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pharmacyclics Llc filed Critical Pharmacyclics Llc
Publication of DOP2015000215A publication Critical patent/DOP2015000215A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/84—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D307/85—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/29—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
    • C07C309/30—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings of six-membered aromatic rings substituted by alkyl groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Furan Compounds (AREA)
  • Steroid Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

TOSILATO ABEXINOSTATO DE LA FÓRMULA (II): Y LA FORMA I CRISTALINA DE ESTE CARACTERIZADO POR EL PATRÓN DE DIFRACCIÓN X EN POLVO DEL MISMO, EL ESPECTRO DE RAMAN DE ESTE, Y EL ESPECTRO DE NMR CP/MAS 13C EN ESTADO SÓLIDO.
DO2015000215A 2013-03-04 2015-09-04 Sal de abexinostato novedosa, forma cristalina relacionada, método de preparación de esta y las composiciones farmacéuticas que la contienen DOP2015000215A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361772191P 2013-03-04 2013-03-04
FR1351898A FR3002733B1 (fr) 2013-03-04 2013-03-04 Nouveau sel de l'abexinostat, forme cristalline associee,leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Publications (1)

Publication Number Publication Date
DOP2015000215A true DOP2015000215A (es) 2015-09-30

Family

ID=48521256

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2015000215A DOP2015000215A (es) 2013-03-04 2015-09-04 Sal de abexinostato novedosa, forma cristalina relacionada, método de preparación de esta y las composiciones farmacéuticas que la contienen

Country Status (39)

Country Link
US (3) US9115108B2 (es)
EP (2) EP3252044A1 (es)
JP (2) JP6449177B2 (es)
CN (2) CN109734690B (es)
AR (1) AR094935A1 (es)
AU (2) AU2014224456B2 (es)
BR (1) BR112015021443A2 (es)
CA (1) CA2903369C (es)
CL (1) CL2015002488A1 (es)
CR (1) CR20150456A (es)
CY (1) CY1119147T1 (es)
DK (1) DK2964622T3 (es)
DO (1) DOP2015000215A (es)
EA (2) EA039113B1 (es)
ES (1) ES2632471T3 (es)
FR (1) FR3002733B1 (es)
GE (1) GEP201706760B (es)
HK (1) HK1220965A1 (es)
HR (1) HRP20171041T1 (es)
HU (1) HUE035299T2 (es)
IL (1) IL241038B (es)
JO (1) JO3402B1 (es)
LT (1) LT2964622T (es)
MA (1) MA38423B1 (es)
ME (1) ME02814B (es)
MX (1) MX355436B (es)
MY (1) MY192027A (es)
NI (1) NI201500122A (es)
PE (1) PE20151591A1 (es)
PL (1) PL2964622T3 (es)
PT (1) PT2964622T (es)
RS (1) RS56224B1 (es)
SG (1) SG11201506952YA (es)
SI (1) SI2964622T1 (es)
TN (1) TN2015000367A1 (es)
TW (1) TWI506023B (es)
UA (1) UA118550C2 (es)
UY (1) UY35356A (es)
WO (1) WO2014135776A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2020004501A (es) 2010-06-03 2021-11-09 Pharmacyclics Llc El uso de inhibidores de la tirosina quinasa de bruton (btk).
KR20180088926A (ko) 2012-07-24 2018-08-07 파마싸이클릭스 엘엘씨 브루톤 티로신 키나제(btk)의 억제제에 대한 내성과 관련된 돌연변이
US20150291554A1 (en) 2012-11-02 2015-10-15 Pfizer Inc. Bruton's Tyrosine Kinase Inhibitors
FR3002733B1 (fr) 2013-03-04 2015-08-14 Servier Lab Nouveau sel de l'abexinostat, forme cristalline associee,leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US9885086B2 (en) 2014-03-20 2018-02-06 Pharmacyclics Llc Phospholipase C gamma 2 and resistance associated mutations
FR3025196B1 (fr) * 2014-09-03 2019-09-06 Pharmacyclics, Inc. Nouveaux sels de 3-[(dimethylamino)methyl]-n-{2-[4-(hydroxycarbamoyl)phenoxy]ethyl}-1-benzofurane-2-carboxamide, formes cristallines associees, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
AU2015311905B2 (en) * 2014-09-03 2020-03-05 Pharmacyclics Llc Novel salts of 3-[(dimethylamino)methyl)-N-{2-(4-(hydroxycarbamoyl) phenoxy)ethyl}-1-benzofuran-2-carboxamide, related crystalline forms, method for preparing the same and pharmaceutical compositions containing the same
FR3025197B1 (fr) * 2014-09-03 2019-09-06 Pharmacyclics, Inc. Nouveau sel de 3-[(dimethylamino)methyl]-n-{2-[4-(hydroxycarbamoyl)phenoxy]ethyl}-1-benzofurane-2-carboxamide, formes cristallines associees, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
WO2017011314A1 (en) * 2015-07-10 2017-01-19 Paharmacyclics Llc Btk and hdac combinations
WO2022261401A1 (en) 2021-06-10 2022-12-15 Teva Pharmaceuticals International Gmbh Solid state forms of abexinostat and process for preparation thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3038004A (en) * 1958-04-18 1962-06-05 Burroughs Wellcome Co Quaternary ammonium compounds
GB0020721D0 (en) * 2000-08-22 2000-10-11 Merck Sharp & Dohme Therapeutic agents
MXPA05010782A (es) * 2003-04-07 2005-12-12 Axys Pharm Inc Nuevos hidroxamatos como agentees terapeuticos.
US20090270497A1 (en) * 2008-04-24 2009-10-29 Pharmacyclics, Inc. Treatment of Non-Localized Inflammation with pan-HDAC Inhibitors
US8603521B2 (en) * 2009-04-17 2013-12-10 Pharmacyclics, Inc. Formulations of histone deacetylase inhibitor and uses thereof
WO2011036647A1 (en) * 2009-09-24 2011-03-31 Ranbaxy Laboratories Limited Process for the preparation of sorafenib tosylate
WO2013039956A2 (en) * 2011-09-14 2013-03-21 The Trustees Of Columbia University In The City Of New York Compositions and methods for treating mood disorders
FR3002733B1 (fr) 2013-03-04 2015-08-14 Servier Lab Nouveau sel de l'abexinostat, forme cristalline associee,leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Also Published As

Publication number Publication date
MA38423A1 (fr) 2017-02-28
BR112015021443A2 (pt) 2017-07-18
DK2964622T3 (en) 2017-07-31
GEP201706760B (en) 2017-10-25
RS56224B1 (sr) 2017-11-30
ES2632471T3 (es) 2017-09-13
CA2903369A1 (en) 2014-09-12
AU2014224456A1 (en) 2015-10-08
PE20151591A1 (es) 2015-11-06
JP6449177B2 (ja) 2019-01-09
LT2964622T (lt) 2017-08-10
US20140249215A1 (en) 2014-09-04
PT2964622T (pt) 2017-07-13
AU2014224456A8 (en) 2015-10-22
EA201891023A1 (ru) 2019-03-29
AU2014224456B2 (en) 2018-01-25
TN2015000367A1 (fr) 2017-01-03
EA030689B1 (ru) 2018-09-28
US20150315167A1 (en) 2015-11-05
TWI506023B (zh) 2015-11-01
IL241038B (en) 2019-09-26
JP2019069955A (ja) 2019-05-09
EA039113B1 (ru) 2021-12-06
ME02814B (me) 2018-01-20
CN109734690A (zh) 2019-05-10
JO3402B1 (ar) 2019-10-20
CA2903369C (en) 2021-06-08
NI201500122A (es) 2018-10-18
AR094935A1 (es) 2015-09-09
CN109734690B (zh) 2023-08-11
EA201591530A1 (ru) 2016-01-29
EP3252044A1 (fr) 2017-12-06
FR3002733A1 (fr) 2014-09-05
CR20150456A (es) 2015-10-21
TW201434822A (zh) 2014-09-16
US9115108B2 (en) 2015-08-25
CN105263917A (zh) 2016-01-20
MY192027A (en) 2022-07-23
IL241038A0 (en) 2015-11-30
WO2014135776A1 (fr) 2014-09-12
AU2018202881A1 (en) 2018-05-17
UY35356A (es) 2014-09-30
SG11201506952YA (en) 2015-10-29
CY1119147T1 (el) 2018-02-14
HUE035299T2 (en) 2018-05-02
CL2015002488A1 (es) 2016-03-11
NZ712380A (en) 2020-10-30
JP2016510735A (ja) 2016-04-11
JP6720280B2 (ja) 2020-07-08
SI2964622T1 (sl) 2017-10-30
MX2015011566A (es) 2016-06-24
EP2964622A1 (fr) 2016-01-13
FR3002733B1 (fr) 2015-08-14
US20170313671A1 (en) 2017-11-02
AU2018202881B2 (en) 2020-02-27
HRP20171041T1 (hr) 2017-10-06
CN105263917B (zh) 2018-11-20
PL2964622T3 (pl) 2017-10-31
US10150748B2 (en) 2018-12-11
HK1220965A1 (zh) 2017-05-19
MA38423B1 (fr) 2017-10-31
UA118550C2 (uk) 2019-02-11
MX355436B (es) 2018-04-18
EP2964622B1 (fr) 2017-04-19

Similar Documents

Publication Publication Date Title
DOP2015000215A (es) Sal de abexinostato novedosa, forma cristalina relacionada, método de preparación de esta y las composiciones farmacéuticas que la contienen
CY1124068T1 (el) Στερεες μορφες ενος εκλεκτικου αναστολεα cdk4/6
CR20150633A (es) Derivados del bipirazol como inhibidores jak
UA116648C2 (uk) Фумарати як проліки та їх застосування при лікуванні різних захворювань
DOP2015000157A (es) Lactamas fusionadas de arilo y heteroarilo
CU20170162A7 (es) Derivados de fenil-tieno(2,3-d)pirimidina-hidroxiácido útiles en el tratamiento del cáncer y enfermedades autoinmunes, método de preparación de los mismos y composiciones farmacéuticas que los contienen
CU20140048A7 (es) Novedosos derivados de purina útiles en el tratamiento del cáncer y trastornos neurodegenerativos
UY34657A (es) ?derivados macrocíclicos para el tratamiento de enfermedades?.
MX2015014298A (es) Compuestos de dihidropirido pirimidina como inhibidores de autotaxina.
UY36070A (es) Triterpenoides con actividad inhibidora de la maduración de hiv
SV2016005310A (es) Derivados de diheterociclo enlazado a cicloalquilo
NI201500176A (es) Derivados de prodroga de triazolpiridinas sustituidas
CR20120655A (es) Forma cristalina delta de la sal de arginina de perindoprilo, su procedimiento de preparación, y las composiciones farmacéuticas que la contienen
EA201791396A1 (ru) ПРОИЗВОДНЫЕ ИМИДАЗОПИРИДАЗИНА В КАЧЕСТВЕ ИНГИБИТОРОВ PI3Kβ
CY1119540T1 (el) Υποκατασταθεντα απο γλυκοπυρανοσυλιο παραγωγα ινδολο-ουριας και η χρηση τους ως αναστολεις sglt
UY35004A (es) Forma amorfa estabilizada de la agomelatina, su procedimiento de preparación y las composiciones farmacéuticas que la contienen
BR112018008319A2 (pt) formulação de fviii
NI201500172A (es) Composiciones farmacéuticas
CO2017007074A2 (es) Sintesis total de trioxacarcina dc-45-a2 y preparación de analogos de trioxacarcina
EA201700037A1 (ru) Производные 2н-хромена в качестве анальгезирующих средств